Mirae Asset Global ETFs Holdings
ADCT icon

Mirae Asset Global ETFs Holdings’s ADC Therapeutics ADCT Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.7K Buy
49,270
+1,360
+3% +$3.97K ﹤0.01% 3030
2026
Q1 		$180K Buy
47,910
+7,883
+20% +$31.1K ﹤0.01% 2416
2025
Q4 		$141K Buy
40,027
+5,982
+18% +$24.3K ﹤0.01% 2511
2025
Q3 		$136K Sell
34,045
-5,588
-14% -$17.6K ﹤0.01% 2521
2025
Q2 		$106K Sell
39,633
-8,930
-18% -$18.8K ﹤0.01% 2584
2025
Q1 		$68.5K Buy
48,563
+2,043
+4% +$3.47K ﹤0.01% 2771
2024
Q4 		$92.6K Buy
46,520
+8,246
+22% +$21.6K ﹤0.01% 2734
2024
Q3 		$121K Buy
+38,274
New +$121K ﹤0.01% 2623

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's ADCT Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its ADC Therapeutics (ADCT) stake by 2.8% in Q2 2026, buying an estimated $3.97K and bringing the position to 49,270 shares worth $52.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3030.

Mirae Asset Global ETFs Holdings first reported a position in ADCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $180K in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 49,270 shares of ADC Therapeutics worth $52.7K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 1,360 ADC Therapeutics shares in Q2 2026, an estimated $3.97K.
  • ADC Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #3030 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in ADC Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Mirae Asset Global ETFs Holdings's ADC Therapeutics position peaked at $180K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.